EWA
CSTL icon

EverSource Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

EverSource Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Buy
139
+119
+595% +$2.65K ﹤0.01% 3486
2026
Q1 		$491 Sell
20
-8
-29% -$262 ﹤0.01% 4072
2025
Q4 		$1.09K Buy
28
+8
+40% +$258 ﹤0.01% 3686
2025
Q3 		$455 Sell
20
-27
-57% -$548 ﹤0.01% 3971
2025
Q2 		$960 Hold
47
– – ﹤0.01% 3751
2025
Q1 		$941 Buy
47
+38
+422% +$941 ﹤0.01% 3251
2024
Q4 		$240 Buy
+9
New +$274 ﹤0.01% 3396
2024
Q3 		– Sell
-7
Closed -$169 – 3050
2024
Q2 		$169 Buy
+7
New +$156 ﹤0.01% 2980

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's CSTL Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Castle Biosciences (CSTL) stake by 595% in Q2 2026, buying an estimated $2.65K and bringing the position to 139 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

EverSource Wealth Advisors first reported a position in CSTL in Q2 2024 and has held it in 8 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • EverSource Wealth Advisors held 139 shares of Castle Biosciences worth $3.31K as of Q2 2026.
  • EverSource Wealth Advisors bought 119 Castle Biosciences shares in Q2 2026, an estimated $2.65K.
  • Castle Biosciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3486 holding.
  • EverSource Wealth Advisors first reported a position in Castle Biosciences in Q2 2024 and has held it in 8 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.